Testicular Cancer from Diagnosis to Epigenetic Factors
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21460%2F17%3A00327980" target="_blank" >RIV/68407700:21460/17:00327980 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/17:10373482 RIV/68407700:21720/17:00327980
Výsledek na webu
<a href="https://doi.org/10.18632/oncotarget.20992" target="_blank" >https://doi.org/10.18632/oncotarget.20992</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.18632/oncotarget.20992" target="_blank" >10.18632/oncotarget.20992</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Testicular Cancer from Diagnosis to Epigenetic Factors
Popis výsledku v původním jazyce
Testicular cancer (TC) is one of the most common neoplasms that occurs in male and includes germ cell tumors (GCT), sex cord-gonadal stromal tumors and secondary testicular tumors. Diagnosis of TC involves the evaluation of serum tumor markers alpha-fetoprotein, human chorionic gonadotropin and lactate dehydrogenase, but clinically several types of immunohistochemical markers are more useful and more sensitive in GCT, but not in teratoma. These new biomarkers are genes expressed in primordial germ cells/gonocytes and embryonic pluripotency-related cells but not in normal adult germ cells and they include PLAP, OCT3/4 (POU5F1), NANOG, SOX2, REX1, AP-2γ (TFAP2C) and LIN28. Gene expression in GCT is regulated, at least in part, by DNA and histone modifications, and the epigenetic profile of these tumours is characterised by genome-wide demethylation. There are different epigenetic modifications in TG-subtypes that reflect the normal developmental switch in primordial germ cells from an under- to normally methylated genome. The main purpose of this review is to illustrate the findings of recent investigations in the classification of male genital organs, the discoveries in the use of prognostic and diagnostic markers and the epigenetic aberrations mainly affecting the patterns of DNA methylation/histone modifications of genes (especially tumor suppressors) and microRNAs (miRNAs).
Název v anglickém jazyce
Testicular Cancer from Diagnosis to Epigenetic Factors
Popis výsledku anglicky
Testicular cancer (TC) is one of the most common neoplasms that occurs in male and includes germ cell tumors (GCT), sex cord-gonadal stromal tumors and secondary testicular tumors. Diagnosis of TC involves the evaluation of serum tumor markers alpha-fetoprotein, human chorionic gonadotropin and lactate dehydrogenase, but clinically several types of immunohistochemical markers are more useful and more sensitive in GCT, but not in teratoma. These new biomarkers are genes expressed in primordial germ cells/gonocytes and embryonic pluripotency-related cells but not in normal adult germ cells and they include PLAP, OCT3/4 (POU5F1), NANOG, SOX2, REX1, AP-2γ (TFAP2C) and LIN28. Gene expression in GCT is regulated, at least in part, by DNA and histone modifications, and the epigenetic profile of these tumours is characterised by genome-wide demethylation. There are different epigenetic modifications in TG-subtypes that reflect the normal developmental switch in primordial germ cells from an under- to normally methylated genome. The main purpose of this review is to illustrate the findings of recent investigations in the classification of male genital organs, the discoveries in the use of prognostic and diagnostic markers and the epigenetic aberrations mainly affecting the patterns of DNA methylation/histone modifications of genes (especially tumor suppressors) and microRNAs (miRNAs).
Klasifikace
Druh
J<sub>SC</sub> - Článek v periodiku v databázi SCOPUS
CEP obor
—
OECD FORD obor
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
Návaznosti výsledku
Projekt
<a href="/cs/project/ED2.1.00%2F03.0091" target="_blank" >ED2.1.00/03.0091: Univerzitní centrum energeticky efektivních budov (UCEEB)</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Oncotarget
ISSN
1949-2553
e-ISSN
1949-2553
Svazek periodika
8
Číslo periodika v rámci svazku
61
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
10
Strana od-do
104654-104663
Kód UT WoS článku
000419562500151
EID výsledku v databázi Scopus
2-s2.0-85035331570